Akademik Veri Yönetim Sistemi
International VETEXPO-2019 Veterinary Sciences Congress, İstanbul, Türkiye, 20 - 22 Eylül 2019, ss.116
The aim of this study was to investigate the effect and toxicity of doxorubicin cyclophosphamide
combination in neoadjuvant use in dogs with locally advanced mammary tumors. In this study,
doxorubicin and cyclophosphamide combination was applied as neoadjuvant chemotherapy to dogs with 8
locally advanced mammary tumors of various breeds aged 8-14 years. A tru-cut biopsy from the mammary
tumor and fine needle aspiration biopsy from the relevant lymph node were obtained from all dogs before
neoadjuvant chemotherapy. The samples were sent to the pathology laboratory for histopathological
examination. Pathology results of the dogs; adenocarcinoma (n: 5), tubulo-papillary carcinoma (n: 2) and
malignant mix tumor (n: 1). Neoadjuvant chemotherapy was determined as doxorubicin 25-30mg / m2 and
cyclophosphamide 100mg / m2 as i.v slow injection and 4 administrations with 3 week intervals. Before
each chemotherapy, the dogs was followed up with blood examination and detailed clinical examination.
Toxicity and efficacy of this treatment were determined by clinical examination, laboratory tests and
measurement of tumor diameter. Although no side effects were observed during treatment as toxicity,
clinical findings such as fever, vomiting, anorexia, lethargy, weight loss, alopecia, enteritis, skin
ulceration, and laboratory findings such as neutropenia and decreased hematocrit values were observed
after treatments. Based on the longest diameters of tumors before and after neoadjuvant chemotherapy;
complete response was detected in 2 dogs (25%), partial response in 2 dogs (25%) and stable disease in 4
dogs (50%). According to preliminary results, the toxicity of doxurubicin and cyclophosphamide
combination in neoadjuvant chemotherapy in dogs with locally advanced mammary tumors is acceptable
and are seen to be promising in treatment.